Edema

Clinical Snapshot

Edema is a clinically visible increase in interstitial fluid volume, produced by expansion of total-body sodium — and the water that follows it — beyond what the interstitium can accommodate without becoming apparent on exam. Firm fingertip pressure that leaves a visible indentation defines pitting edema; when no indentation forms, it is nonpitting, a clue that points away from simple volume overload toward lymphatic obstruction or myxedema instead. Severe, generalized edema is called anasarca. The single most important branch point in evaluating any patient with edema is whether it is unilateral or bilateral: unilateral edema points toward a local structural problem — deep vein thrombosis, chronic venous insufficiency, lymphedema, or local infection/inflammation — while bilateral edema points toward a systemic cause such as heart failure, cirrhosis, nephrotic syndrome or another significant kidney disease, hypoalbuminemia, hypothyroidism, or a causative medication. Edema is a sign, not a diagnosis in itself — the underlying disorder must be identified and treated concurrently with any therapy directed at the fluid.^[1]

Recognize the Condition

Examination technique

Apply firm fingertip pressure over a bony surface — classically the anterior tibia — for several seconds. Pitting edema leaves a visible, palpable indentation that resolves over seconds; nonpitting edema does not indent, and should prompt consideration of lymphedema or hypothyroidism (myxedema) rather than simple volume overload.

Distribution

Edema follows gravity and body position: it appears first in the feet and ankles in an ambulatory patient, over the sacrum in a patient who is recumbent, and in the scrotum in a supine man with significant fluid overload. Periorbital edema, especially noticed on waking, is a classic early sign of nephrotic-range proteinuria. Fluid can also compartmentalize into a body cavity instead of (or in addition to) subcutaneous tissue — ascites (peritoneal), pleural effusion, or pericardial effusion.

Unilateral vs. bilateral edema — the key diagnostic branch point

Unilateral (or clearly asymmetric) edema

Suggests a local structural cause on the affected side: deep vein thrombosis, chronic venous insufficiency, lymphedema (from malignancy, prior lymph node dissection or radiation, or a prior surgical/vascular-access procedure on that limb — e.g., saphenous vein harvest for CABG, or a prior arteriovenous fistula/graft), or localized infection or inflammation (e.g., cellulitis, an insect sting, or a snake bite). Investigate the affected limb specifically rather than pursuing a broad systemic workup first.

Bilateral (symmetric) edema

Suggests a systemic cause: heart failure, cirrhosis or another hepatic dysfunction, nephrotic syndrome or another significant kidney disease, hypothyroidism, pregnancy, a capillary-leak state, hypoalbuminemia, or a causative medication. Bilateral chronic venous insufficiency and bilateral lymphedema also occur and remain on the differential, but only after the systemic causes above have been reasonably excluded.

Risk Factors

Systemic conditions: heart failure, cirrhosis or other hepatic dysfunction, nephrotic syndrome or other significant kidney disease, hypothyroidism, pregnancy, hypoalbuminemia (malnutrition, protein-losing states), and capillary-leak states.
Localized conditions: venous or lymphatic obstruction (including malignancy compressing venous/lymphatic drainage), deep vein thrombosis, chronic venous insufficiency, infection or inflammation, and sequelae of prior limb surgery or vascular-access procedures.
Medications — a large, genuinely pharmacist-relevant list; see Assessment & Diagnosis and Drug Tables for the full medication-class breakdown.
High dietary sodium intake relative to the ability to excrete it.
Prolonged standing or sitting, immobility, and obesity — particularly relevant to idiopathic edema, which occurs almost exclusively in this group.
Advanced age and polypharmacy, which increase both the prevalence of edema-associated comorbidities and cumulative exposure to edema-causing medications.

Red Flags & Refer

Most peripheral edema is a chronic, non-emergent finding that can be worked up over days, but the following presentations need urgent same-day (or emergency) evaluation:

Unilateral leg swelling with pain, warmth, or calf tenderness — suggests deep vein thrombosis and needs urgent evaluation (D-dimer and/or compression ultrasonography) rather than a routine outpatient workup.
Sudden-onset facial, lip, tongue, or airway swelling — suggests angioedema, a true emergency requiring immediate airway assessment, not a diuretic or a routine edema workup.
Signs of decompensated heart failure — rapid weight gain, worsening dyspnea or orthopnea, or hypoxia — or signs of acute kidney injury (oliguria, rapidly rising creatinine).
Rapidly progressive ascites or edema in a patient with known cirrhosis — suggests spontaneous bacterial peritonitis or another acute hepatic decompensation and needs urgent assessment (including diagnostic paracentesis), not simply an increased diuretic dose.
Symptoms or signs of significant intravascular volume depletion during diuretic therapy — confusion, dizziness, hypotension, or a marked drop in urine output — which need prompt reassessment rather than continued dose escalation.
New, severe, generalized edema (anasarca) with respiratory compromise.

Assessment & Diagnosis

History

Onset, duration, and whether the edema is unilateral or bilateral (see Recognize the Condition) — this single question narrows the differential more than any other.
Ask specifically about conditions associated with edema: known kidney, heart, or liver disease; pregnancy; low serum albumin or a protein-losing condition; a capillary-leak state; and hypothyroidism.
For unilateral edema, ask about recent immobility or travel, active malignancy, prior lymph node dissection or radiation, prior limb surgery or vascular-access procedures, and any signs of infection or inflammation.
Take a careful dietary sodium history.
Take a complete medication history, including nonprescription products and natural health products — medication-induced edema is common, frequently missed, and often reversible simply by identifying and addressing the causative drug (see the medication table below).

Physical examination

Weight — the single most sensitive measure of change in total-body fluid, and the basis for tracking response to therapy.
Blood pressure and heart rate — hypertension is a feature of expanded extracellular fluid volume (ECFV); hypotension, especially a postural drop, suggests contracted ECFV instead.
Respiratory rate and oxygen saturation.
Skin turgor and skin appearance (shine or taut skin over expanded tissue).
Jugular venous pressure — elevated JVP, along with ascites and pleural effusion, are features of ECFV expansion; loss of skin turgor with a low JVP instead suggests ECFV contraction.
Abdominal exam and percussion for ascites; chest percussion/auscultation for a pleural effusion.
Characterize the edema itself: pitting vs nonpitting, symmetric vs asymmetric, and its distribution.

Laboratory investigations

Electrolytes — sodium, potassium, chloride, bicarbonate, calcium, and magnesium.
Urea and creatinine (kidney function), and uric acid.
Urinalysis, specifically looking for significant albuminuria (nephrotic syndrome).
Liver function tests, with particular attention to markers of synthetic hepatic function — INR, albumin, and ammonia.
TSH, fasting blood glucose, and a lipid profile.
A natriuretic peptide (BNP or NT-proBNP) to screen for a cardiac cause.
Serum albumin — low in liver disease or a proteinuric kidney disease.
A 24-hour urine collection to quantify proteinuria and sodium excretion when signs/symptoms suggest a primary or secondary kidney disorder, or to confirm dietary sodium adherence during a resistant-edema workup.

Imaging

Chest x-ray — assesses cardiac size and pulmonary status.
Point-of-care ultrasound (POCUS) — lung POCUS can identify interstitial edema and pleural effusion; cardiac POCUS can identify pericardial effusion; inferior vena cava imaging gives a rapid estimate of central venous pressure/volume status.
Compression ultrasonography of the affected limb whenever unilateral edema raises concern for deep vein thrombosis.

When testing is not needed

A patient with mild, bilateral, pitting edema, a clearly identified recently-started causative medication, an otherwise normal history and exam, and no red flags does not need the full systemic laboratory/imaging workup above before a trial of discontinuing or switching the offending drug. Reserve the complete workup for edema without an obvious explanation, edema that persists despite an appropriate medication change, or edema with any red-flag feature.^[1]

Medications that can cause or worsen edema

Drug-induced peripheral edema is common and frequently under-recognized — always review the medication list before assuming new or worsening edema reflects a new or worsening systemic disease.^[2]

The highest-yield medication-induced edema causes for pharmacists to screen for

Dihydropyridine calcium channel blockers

Amlodipine, nifedipine, and felodipine cause edema through precapillary arteriolar vasodilation that raises capillary hydrostatic pressure — a hemodynamic effect, not fluid retention, so it does not respond to a diuretic. It is dose-dependent and more common at higher doses; non-dihydropyridine agents (diltiazem, verapamil) cause it far less often. Management is a dose reduction, a switch to a non-dihydropyridine agent or a different antihypertensive class, or adding a low-dose ACE inhibitor/ARB (which counteracts the arteriolar vasodilation) if the dihydropyridine must be continued.

NSAIDs

Celecoxib, naproxen, and other NSAIDs (including COX-2-selective agents) cause sodium and water retention through renal prostaglandin inhibition, and can also blunt the effect of a diuretic being used for another indication. Recommend acetaminophen for routine analgesia instead whenever a patient on diuretic therapy, or with a condition prone to fluid overload, needs pain control.

Thiazolidinediones

Pioglitazone causes fluid retention through increased renal sodium reabsorption and increased vascular permeability; the risk is substantially higher when combined with insulin. Avoid in patients with existing heart failure and reconsider use in any patient who develops new edema while taking it.

Gabapentinoids

Gabapentin and pregabalin cause peripheral edema through a vasodilatory mechanism, dose-dependently — a well-recognized, clinically significant adverse effect rather than an incidental finding, and worth specifically checking during a medication review for a patient who develops new edema after starting or increasing either drug.

Corticosteroids

Prednisone and other corticosteroids with mineralocorticoid activity cause sodium and water retention; the effect is dose- and duration-dependent and generally reversible on tapering.

Full medication-class reference

Medication class	Example agents
Antidepressants	Escitalopram, mirtazapine, paroxetine, venlafaxine
Antiepileptics	Carbamazepine, clobazam, valproic acid
Antihypertensives	Alpha-1 blockers, beta-blockers, dihydropyridine calcium channel blockers, minoxidil
Antipsychotics	Clozapine, olanzapine, quetiapine, risperidone
Antispastics	Baclofen
Calcineurin inhibitors	Cyclosporine, tacrolimus
Checkpoint inhibitors	Nivolumab
Corticosteroids	Prednisone
Estrogens	Estradiol
Gabapentinoids	Gabapentin, pregabalin
NSAIDs	Celecoxib, naproxen
Opioids	Hydromorphone, morphine, oxycodone, tramadol
Progestins	Progesterone
Protein kinase inhibitors	BCR-ABL inhibitors (bosutinib, dasatinib, imatinib), VEGF-pathway inhibitors (sunitinib)
Proton pump inhibitors	Lansoprazole, omeprazole, pantoprazole
Thiazolidinediones	Pioglitazone
Selective estrogen receptor modulators (SERMs)	Tamoxifen

Treatment Targets

Decrease excess extracellular fluid volume and reduce or eliminate visible edema, at a controlled and physiologically safe rate.
Identify and directly treat the underlying cause of the edema in parallel with any symptomatic fluid-directed therapy.
Improve patient comfort and mobility, and prevent edema-related skin breakdown or infection.
Avoid iatrogenic harm from diuretic therapy — intravascular volume depletion, electrolyte disturbance, and prerenal azotemia.
Recognize and manage diuretic resistance early rather than continuing an ineffective regimen.

Choose Initial Treatment

Direct treatment rule

Treat the underlying cause of the edema first — a diuretic (or compression, for a local cause) is symptomatic therapy layered on top of cause-directed treatment, never a substitute for it.

Do not use diuretics as first-line therapy for edema due to chronic venous insufficiency or lymphedema — these are mechanical/structural problems of impaired venous or lymphatic return, not sodium/volume excess, and a diuretic does not correct the underlying mechanism. 1st line for venous insufficiency/lymphedema is compression therapy (see Non-Pharmacologic Treatment) — reserve a diuretic trial for a patient with a genuinely mixed picture (confirmed systemic volume overload plus venous/lymphatic disease).^[3]

Bilateral edema from a systemic cause (heart failure, kidney disease, cirrhosis) is treated with sodium restriction plus a diuretic, selected and dosed by the underlying cause and kidney function.

Kidney function ClCr 50 mL/min or under, or a cardiac/hepatic cause — start a loop diuretic (furosemide is first-choice; see Drug Tables for full dosing). Kidney function over ClCr 50 mL/min without a cardiac/hepatic cause — a thiazide diuretic is a reasonable initial choice, and is also an effective antihypertensive if hypertension coexists.

For edema due to hepatic cirrhosis specifically, start a combination of spironolactone plus furosemide together, rather than a loop diuretic alone — see Drug Tables for the specific starting ratio and titration.^[4]

Medication-induced edema — identify and address the causative drug (dose reduction, switch, or discontinuation as clinically appropriate) as the primary intervention; a diuretic is a poor substitute for removing the actual cause and is not routinely indicated for this cause alone.

Do not start a diuretic in idiopathic edema without first exhausting non-pharmacologic measures — diuretic use, and especially stopping and restarting a diuretic, can itself precipitate cyclical fluid shifts in this specific population; reserve intermittent diuretic therapy for when nonpharmacologic measures genuinely fail.

Do not use diuretics in pregnancy for edema — refer to a specialist in hypertensive disorders of pregnancy instead (see Special Populations).

Non-Pharmacologic Treatment

Sodium restriction to under 88 mmol/day (2 g sodium, or 5 g sodium chloride) is the foundation of therapy for any volume-overload-related edema — a diuretic will not work if sodium intake continues to exceed what is being excreted.
Fluid restriction, individualized to the patient's volume status and disease state — particularly important, and generally under 1 L/day, when significant hyponatremia (sodium under 130 mmol/L) is also present.
Avoid the supine position in decompensated heart failure, especially at night, since it augments venous return and can worsen orthopnea/paroxysmal nocturnal dyspnea — advise a more upright sleeping position instead.
Leg elevation above the level of the heart when resting, to promote venous and lymphatic return.
1st line for venous insufficiency and lymphedema compression therapy: a medium-pressure compression stocking (20-30 mmHg) for most patients with venous insufficiency; complete decongestive therapy (manual lymphatic drainage, multilayer compression bandaging, exercise, and skin care) for confirmed lymphedema. Avoid high-pressure compression in significant peripheral arterial disease, where it can worsen limb ischemia — confirm adequate arterial perfusion before fitting a higher-pressure garment.^[3]
Paracentesis for tense or refractory ascites, performed under specialist direction.
Ultrafiltration therapy for significant, diuretic-refractory volume overload in the setting of kidney insufficiency — refer to a specialist.
Meticulous skin care and prompt treatment of any skin breakdown in lymphedema, to reduce the risk of cellulitis and further lymphatic damage.

Pharmacologic Treatment Options

Drug / intervention	Role	Dose / use	Important adverse effects	Teaching points
Furosemide Preferred	Loop diuretic — edema from a cardiac, renal, or hepatic cause, any kidney function	20-80 mg PO as a single morning dose, increase by 20-40 mg increments if response is inadequate	Hypokalemia, hyponatremia, dehydration, ototoxicity at high IV doses	First-choice diuretic for most cause-directed edema. Give in the morning to avoid nighttime diuresis. See Drug Tables for full titration.
Hydrochlorothiazide Alternative	Thiazide diuretic — mild edema with preserved kidney function (ClCr over 50 mL/min)	25-100 mg PO daily	Hyponatremia (more common than with loop diuretics), hypokalemia, hyperglycemia at higher doses	Ineffective as monotherapy if ClCr is 50 mL/min or under. Useful add-on to a loop diuretic for resistant edema.
Spironolactone Preferred	Aldosterone antagonist — preferred for hepatic-cause edema (with furosemide) and add-on for hypokalemia-prone patients	Cirrhosis: 100 mg PO daily with furosemide 40 mg (see Drug Tables for the ratio); other causes: 25 mg PO daily, titrate	Hyperkalemia, gynecomastia	Avoid with significant kidney impairment or baseline hyperkalemia.
Metolazone Special situation	Add-on thiazide-type diuretic for resistant edema despite an adequate loop diuretic dose	2.5-10 mg PO daily, added intermittently	Profound hypokalemia/dehydration risk when combined with a loop diuretic	Give 30-60 minutes before an IV loop diuretic dose if oral. Reserve for experienced clinicians given the electrolyte-depletion risk.
Amiloride Special situation	Potassium-sparing add-on when hypokalemia complicates loop/thiazide therapy	5-10 mg PO daily	Hyperkalemia	Avoid in significant kidney impairment; monitor potassium closely.
Tolvaptan Special situation	Vasopressin V2-receptor antagonist for volume overload with significant hyponatremia refractory to other measures	Specialist-initiated inpatient titration; see Drug Tables	Overly rapid sodium correction (osmotic demyelination risk), hepatotoxicity with prolonged use	Specialist-directed only, with close inpatient sodium monitoring — not routine diuretic therapy.
Compression stockings (20-30 mmHg) Preferred	1st-line therapy for venous-insufficiency or lymphedema-related edema	Worn daily, fitted to the patient	Discomfort or skin irritation if poorly fitted	Not a substitute for diuretics in systemic volume overload — and diuretics are not a substitute for this in venous/lymphatic disease. The two edema mechanisms need different first-line therapy.

Special Populations

Pregnancy

Refer any pregnant patient with new or worsening edema to a specialist in hypertensive disorders of pregnancy. Diuretics are not routinely recommended in pregnancy — they can cause intravascular volume contraction and impair placental perfusion, which has been implicated in the development of gestational preeclampsia. Mild, dependent lower-extremity edema is a common, usually benign finding in pregnancy on its own, but edema accompanied by hypertension, headache, visual changes, or epigastric pain needs urgent preeclampsia assessment.

Breastfeeding

Postpartum edema is usually self-limiting. When a diuretic is genuinely needed in a breastfeeding patient, hydrochlorothiazide and spironolactone both transfer into breast milk only in very low amounts, with no adverse infant effects reported, so either can be used; avoid intense diuresis, since in theory it can reduce milk supply through intravascular volume depletion.

Pediatrics

This chapter addresses adult edema evaluation and management. New pediatric edema needs pediatric-specific evaluation — nephrotic syndrome and congenital heart disease are more prominent considerations in this age group — refer to pediatrics or pediatric nephrology/cardiology rather than extrapolating adult dosing directly.

Renal impairment

Thiazide diuretics are ineffective as monotherapy once ClCr falls to 50 mL/min or under — a loop diuretic is required, often at a higher dose than in a patient with normal kidney function, since higher plasma concentrations are needed to deliver adequate drug into the tubular lumen. Avoid potassium-sparing diuretics (amiloride, spironolactone, eplerenone, finerenone) in significant kidney impairment given a substantially increased hyperkalemia risk; when they are used despite this, monitor potassium closely.

Hepatic impairment

Spironolactone combined with furosemide is the preferred regimen for cirrhotic ascites/edema (see Drug Tables). Avoid NSAIDs entirely in decompensated cirrhosis — they blunt diuretic response and increase acute kidney injury risk. Correct electrolyte disturbances promptly, since both hypokalemia and metabolic alkalosis can precipitate hepatic encephalopathy.

Older adults

Older patients are more susceptible to diuretic-induced dehydration, hypotension, falls, and thiazide-associated hyponatremia — start at the lower end of the dosing range and titrate more gradually, with closer monitoring.

Monitoring & Follow-Up

Weigh the patient at baseline and regularly through treatment — daily during active diuresis, since weight is the most sensitive marker of fluid-status change. The maximum recommended rate of weight loss is 1 kg/day when significant peripheral edema is present, to avoid depleting intravascular volume faster than interstitial fluid can be mobilized into it.^[5]

Check electrolytes (sodium, potassium, chloride, bicarbonate, calcium, magnesium) and kidney function (urea, creatinine) before starting diuretic therapy, again within the first 1-2 weeks of starting or increasing the dose, and periodically thereafter — more frequently when initiating therapy, increasing the dose, adding a second diuretic, or when the patient is clinically unwell (vomiting, diarrhea, reduced oral intake).

Watch specifically for hypokalemia and hyponatremia with loop and thiazide diuretics — both are more common in the first 1-2 weeks of therapy and are usually asymptomatic, so they must be actively checked for rather than waited on — for hyperkalemia with potassium-sparing agents (especially in kidney impairment, diabetes, or with a concurrent ACE inhibitor/ARB), and for prerenal azotemia and metabolic alkalosis with any combination diuretic regimen.

Watch for signs of overdiuresis at every visit — confusion, dizziness, fatigue, hypotension, or weakness clinically, or laboratory evidence of prerenal azotemia, hypokalemia, or metabolic alkalosis — and hold the diuretic (and consider holding other antihypertensives), provide gentle hydration, and consider specialist referral if these develop.

Confirm the underlying cause of the edema is being actively addressed, not just the fluid itself, at every follow-up.

Treatment Failure / Next Step

Confirm adherence to sodium restriction; a 24-hour urine sodium collection can objectively assess dietary adherence if genuinely uncertain.
Confirm adherence to fluid restriction if hyponatremia is present.
Confirm the prescribed diuretic regimen (drug, dose, and frequency) is actually being taken as directed.
Increase the loop diuretic dose incrementally — doubling the dose approximately every 3-5 days — until diuresis is achieved, recognizing that severe hypoalbuminemia (albumin under 20 g/L) or reduced kidney perfusion (kidney failure, heart failure) can impair delivery of the drug into the tubular lumen and blunt the response to an initial dose.
Increase dosing frequency to 2-3 times daily if diuresis is not sustained across the day, and double the dose when switching from IV to oral administration.
Consider IV dosing if the gut is edematous (impairing oral absorption) or in a low-cardiac-output state, and consider a continuous IV infusion in a critical-care setting.
Recognize that a maximum effective dose exists for every loop diuretic — beyond it, further dose increases add toxicity risk without meaningfully more diuresis. At that point, add a second diuretic rather than continuing to escalate the same agent.
Add a distally-acting diuretic (e.g., metolazone or another thiazide) to a loop diuretic for additive blockade at a second nephron site — give the oral thiazide 30-60 minutes before an IV loop diuretic dose, or at the same time if both are given orally.
Add a potassium-sparing diuretic if hypokalemia complicates therapy, with caution and frequent electrolyte monitoring in kidney failure, diabetes, or with concurrent ACE inhibitors, ARBs, beta-blockers, cyclosporine, NSAIDs, pentamidine, tacrolimus, or trimethoprim, given real hyperkalemia risk in combination.
Consider a carbonic anhydrase inhibitor (acetazolamide) as a specialist-directed addition when diuresis remains inadequate despite combination therapy, or when metabolic alkalosis is itself limiting further loop/thiazide titration — monitor bicarbonate and potassium closely given the risk of significant metabolic acidosis or hypokalemia.
If all of the above fail, refer for a specialist-directed procedural option: ultrafiltration for kidney failure, or paracentesis for cirrhotic ascites.

Common Errors to Avoid

Starting a diuretic for edema due to chronic venous insufficiency or lymphedema instead of compression therapy — diuretics do not correct the underlying mechanical problem.
Missing a causative medication (a dihydropyridine calcium channel blocker, an NSAID, a thiazolidinedione, a gabapentinoid, or a corticosteroid are the highest-yield culprits) and adding a diuretic on top of an ongoing offending drug instead of addressing it directly.
Using a fixed-dose combination diuretic product as first-line therapy — it is harder to titrate the individual components up or down as the patient's volume status changes.
Diuresing faster than roughly 1 kg/day of weight loss, risking intravascular volume depletion out of proportion to interstitial fluid mobilization.
Using a potassium-sparing diuretic in significant kidney impairment without close, frequent potassium monitoring.
Missing early signs of overdiuresis (confusion, dizziness, hypotension, prerenal azotemia) and continuing to escalate the diuretic dose instead of reassessing.
Treating unilateral edema as if it were bilateral/systemic — this misses deep vein thrombosis and lymphedema, which need their own specific workup and treatment.
Assuming a thiazide diuretic will be effective as monotherapy once kidney function has fallen to a creatinine clearance of about 50 mL/min or under.
Continuing, or repeatedly restarting, a diuretic in idiopathic edema despite evidence that stopping and starting is itself driving cyclical fluid shifts.
Missing spontaneous bacterial peritonitis or another acute decompensation in a cirrhotic patient with rapidly worsening ascites, instead of simply increasing the diuretic dose.
Using an NSAID in a patient on diuretic therapy for edema — it blunts the diuretic response and increases kidney injury risk.

Clinical Decision Algorithm

Initial evaluation of new peripheral edema

New peripheral edema identified

Determine unilateral vs bilateral distribution and screen for red flags

Unilateral / asymmetric edema

Evaluate for DVT (D-dimer / compression ultrasound), chronic venous insufficiency, lymphedema, or local infection/inflammation

DVT confirmed or suspected

Manage as suspected DVT — urgent workup and treatment, not a diuretic problem

Venous insufficiency or lymphedema confirmed

Compression therapy first-line; diuretics not indicated unless a mixed picture with confirmed systemic overload is also present

Bilateral / symmetric edema

Review the medication list for a causative drug — CCB, NSAID, thiazolidinedione, gabapentinoid, corticosteroid, and others

Causative medication identified

Address the causative drug — dose reduction, switch, or discontinuation — as the primary intervention

No causative medication, or edema persists after addressing it

Complete systemic workup: history, exam, electrolytes, renal/liver function, TSH, natriuretic peptide, urinalysis, imaging as indicated

Identify the underlying cause — heart failure, cirrhosis, nephrotic syndrome/kidney disease, hypothyroidism, hypoalbuminemia, idiopathic, or none identified

Diuretic selection for confirmed systemic (cardiac/renal/hepatic) bilateral edema

Systemic cause confirmed and being treated directly; sodium restriction under 88 mmol/day (2 g sodium) in place

ClCr over 50 mL/min, no cardiac/hepatic cause

Thiazide diuretic (e.g., hydrochlorothiazide 25-100 mg PO daily)

ClCr 50 mL/min or under, or a cardiac cause

Loop diuretic (furosemide 20-80 mg PO daily initial, titrate)

Hepatic cirrhosis

Spironolactone + furosemide combination in a fixed ratio (see Drug Tables)

Monitor daily weight and electrolytes/renal function; target under 1 kg/day weight loss

Adequate response

Continue at the lowest effective dose; reassess periodically

Inadequate response (resistant edema)

Work through the resistant-edema sequence: confirm adherence, increase loop diuretic dose/frequency, add a distal diuretic, add a potassium-sparing agent, consider a carbonic anhydrase inhibitor, then refer for ultrafiltration/paracentesis if still refractory

Drug Tables

How to use this table: Doses are adult doses and require patient-specific confirmation, including renal/hepatic adjustment. Select any drug name to open its complete Pharmasist Drug Database page.

Loop diuretics

Most potent diuretic class; first-choice for edema of cardiac, renal, or hepatic origin, and for any edema needing prompt volume reduction.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Furosemide	Initial: 20-80 mg PO as a single dose, preferably in the morning Titration: Increase by 20-40 mg increments every 6-8 hours if response is inadequate IV: 20-40 mg IV as a single dose, may repeat; continuous infusion 3-20 mg/h titrated to response in select critical-care settings Severe/resistant edema: Under specialist direction only, a 500 mg oral tablet strength is available for patients with ClCr 5-20 mL/min not responding to conventional doses	Hypokalemia, hyponatremia, hypochloremia, hypomagnesemia, hyperuricemia, dehydration, prerenal azotemia, ototoxicity (especially with rapid high-dose IV administration)	Aminoglycosides/cisplatin (additive ototoxicity), NSAIDs (reduced diuretic effect, renal risk), digoxin (arrhythmia risk if hypokalemic), lithium (reduced clearance, toxicity), thiazides (synergistic diuresis and electrolyte loss)	First-choice loop diuretic. Onset (oral) 30-60 minutes, duration 4-8 hours. Give in the morning to avoid nighttime diuresis. Effectiveness may be reduced by gut wall edema — consider IV dosing in that setting.
Bumetanide	Initial: 0.5-2 mg PO as a single dose, maximum 10 mg/day Titration: A second and third dose may be given at 4-5 hour intervals if response is inadequate; may also be given BID Maintenance: Lowest effective daily dose	Hypokalemia, hyponatremia, hypochloremia, hyperuricemia, dehydration, ototoxicity, myalgia at high doses	Same loop-diuretic-class interactions as furosemide	1 mg bumetanide produces a diuretic response roughly similar to furosemide 40 mg. No clear efficacy advantage over furosemide despite higher oral bioavailability. The IV formulation is not available in Canada.
Ethacrynic acid	Initial: 50 mg PO as a single dose, after a meal Titration: Increase in 25-50 mg increments daily to desired response; up to 200 mg BID in severe, refractory edema Maintenance: Lowest effective daily dose	Hypokalemia, hyponatremia, dehydration, ototoxicity (higher risk than other loop diuretics at high doses), myalgia	Same loop-diuretic-class interactions as furosemide	Reserve for patients with a genuine sulfonamide hypersensitivity — the only loop diuretic that is not a sulfonamide derivative. Start low (25 mg) and titrate slowly when adding to another diuretic.

Thiazide and thiazide-like diuretics

First-line if ClCr is over 50 mL/min; ineffective as monotherapy once ClCr falls to 50 mL/min or under. Useful antihypertensive effect and useful add-on to a loop diuretic for resistant edema.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Hydrochlorothiazide	Dosing: 25-100 mg PO daily, or divided BID-TID Alternate-day dosing: May be given every other day	Hyponatremia (more common than with loop diuretics), hypokalemia, hyperuricemia, hypercalcemia, hyperglycemia at higher doses, orthostatic hypotension	Loop diuretics (synergistic diuresis for resistant edema), digoxin (arrhythmia risk if hypokalemic), lithium (reduced clearance, toxicity), NSAIDs (reduced effect), antidiabetic medications (may raise blood glucose at higher doses)	Ineffective as monotherapy if ClCr is 50 mL/min or under.
Chlorthalidone	Dosing: 50-100 mg PO once daily, or on alternate days	Same thiazide-class effects as hydrochlorothiazide	Same thiazide-class interactions as hydrochlorothiazide	Longer half-life and generally more potent than hydrochlorothiazide, but no major clinical advantage over an adequate hydrochlorothiazide dose in a patient with normal kidney function. Ineffective as monotherapy if ClCr is 50 mL/min or under.
Indapamide	Initial: 2.5 mg PO once daily Titration: Increase to 5 mg daily if no response within 1 week	Same thiazide-class effects as hydrochlorothiazide	Same thiazide-class interactions as hydrochlorothiazide	Take with food to reduce GI upset. Ineffective as monotherapy if ClCr is 50 mL/min or under.
Metolazone	Dosing: 2.5-10 mg PO daily, as a single dose Add-on to a loop diuretic: Given intermittently, e.g., a few times per week, under close monitoring of weight, kidney function, and potassium	Profound hypokalemia, hyponatremia, dehydration, and prerenal azotemia when combined with a loop diuretic — the electrolyte-depletion risk is higher than with hydrochlorothiazide	Additive hypokalemia/dehydration with loop diuretics; reduced effect with NSAIDs; lithium toxicity	Remains effective even in significant kidney impairment, unlike other thiazides — the preferred distal add-on agent for loop-diuretic-resistant edema. Give the oral dose 30-60 minutes before an IV loop diuretic, or at the same time if both are given orally.

Potassium-sparing diuretics

Useful combined with a loop or thiazide diuretic for resistant edema, or to offset loop/thiazide-induced hypokalemia. Avoid in significant kidney impairment given hyperkalemia risk.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Amiloride	Initial: 5 mg PO daily Titration: Increase to 10 mg daily if needed; may increase further to 15-20 mg daily with careful electrolyte monitoring for persistent hypokalemia Renal adjustment: ClCr 10-50 mL/min: administer 50% of the normal dose	Hyperkalemia (common as monotherapy, especially in kidney impairment, diabetes, and older patients), headache	ACE inhibitors/ARBs (hyperkalemia), potassium supplements (hyperkalemia — avoid unless documented hypokalemia), tacrolimus/cyclosporine (hyperkalemia), NSAIDs (reduced diuretic effect)	Avoid in significant kidney impairment.
Spironolactone	General edema, initial: 25 mg PO daily, increase by 25-50 mg every 5 days to a maximum of 200 mg daily Cirrhotic ascites, initial: 100 mg PO daily, combined with furosemide 40 mg daily Renal adjustment: ClCr 10-50 mL/min: dose every 12-24 hours; ClCr under 10 mL/min: avoid	Hyperkalemia (common as monotherapy, especially in kidney impairment, diabetes, and older patients), gynecomastia, hyponatremia	ACE inhibitors/ARBs (hyperkalemia), potassium supplements (hyperkalemia), tacrolimus/cyclosporine (hyperkalemia), NSAIDs (reduced effect), digoxin (increased digoxin levels, and false elevation on some assays), salicylates (sodium retention)	Preferred first agent, combined with furosemide, for cirrhotic ascites/edema given renin-angiotensin-aldosterone system activation in liver disease (see the cirrhotic ascites note below).
Eplerenone	Initial: 25 mg PO once daily, or every other day Maximum: 50 mg PO daily Renal adjustment: ClCr 30-50 mL/min: maximum 25 mg daily; avoid if ClCr is under 30 mL/min	Hyperkalemia, dehydration, dizziness, diarrhea, nausea	ACE inhibitors/ARBs (hyperkalemia), strong CYP3A4 inhibitors (increased eplerenone levels — avoid combination, e.g., clarithromycin, ketoconazole)	More selective for the mineralocorticoid receptor than spironolactone, with less gynecomastia and fewer sexual side effects — an alternative when those limit spironolactone.
Finerenone	Dosing: 10-20 mg PO once daily, selected by kidney function	Hyperkalemia, hyperuricemia, hypotension	Contraindicated with strong CYP3A4 inhibitors (e.g., itraconazole); avoid strong CYP3A4 inducers (e.g., rifampin, phenobarbital); grapefruit juice significantly increases levels; increased hyperkalemia risk with ACE inhibitors/ARBs	Nonsteroidal mineralocorticoid receptor antagonist. Not recommended if eGFR is under 25 mL/min/1.73m2. Check potassium 4 weeks after initiation and after any dose change. Do not initiate if potassium exceeds 5 mmol/L.

Cirrhotic ascites/edema — combination ratio dosing: start spironolactone 100 mg plus furosemide 40 mg together, once daily. If the response is inadequate after 3-5 days, increase both together in the same 100:40 ratio (e.g., to 200 mg/80 mg, then 300 mg/120 mg) to a maximum of spironolactone 400 mg plus furosemide 160 mg daily. Target weight loss is up to 0.5 kg/day in a patient with ascites but no peripheral edema, and up to 1 kg/day when peripheral edema is also present, to avoid depleting intravascular volume faster than ascitic fluid can be mobilized.^[4]

Carbonic anhydrase inhibitor

Specialist-directed only; reserved for diuresis that remains inadequate on combination loop/thiazide/potassium-sparing therapy, or when that combination has produced a metabolic alkalosis that is itself limiting further titration.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Acetazolamide	Resistant edema, specialist-directed: Per specialist protocol, typically added intermittently to an existing loop/thiazide regimen	Metabolic acidosis, hypokalemia, paresthesias	Additive hypokalemia with loop/thiazide diuretics and corticosteroids	Monitor bicarbonate and potassium closely given the risk of significant metabolic acidosis or hypokalemia.

Vasopressin V2-receptor antagonist

The only selective vasopressin V2-receptor antagonist (vaptan) available in Canada. Reserve for volume overload with significant hyponatremia refractory to other measures, under specialist direction with close inpatient sodium monitoring — not first-line diuretic therapy.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Tolvaptan	Dosing: Per specialist-directed, product-specific inpatient titration protocol	Overly rapid serum sodium correction (osmotic demyelination risk), thirst, dry mouth, hepatotoxicity with use beyond 30 days	Strong CYP3A4 inhibitors increase levels (e.g., ketoconazole, clarithromycin); avoid with strong CYP3A4 inducers	Specialist-initiated inpatient titration only.

Evidence note: Diuretic dosing, adverse effects, and comments reflect standard Canadian practice, cross-checked against current diuretic pharmacology literature.^[5]

References

Peripheral Edema: Evaluation and Management in Primary Care — American Family Physician (Patel H, Skok C, DeMarco A). Am Fam Physician 2022;106(5):557-564
Drug-induced peripheral oedema: an aetiology-based review — British Journal of Clinical Pharmacology (Largeau B, Cracowski JL, Lengellé C, Sautenet B, Jonville-Bera AP). Br J Clin Pharmacol 2021;87(8):3043-3055
2025 SCAI Clinical Practice Guidelines for the Management of Chronic Venous Disease — Journal of the Society for Cardiovascular Angiography & Interventions (Attaran RR, Edwards ML, Arena FJ, et al.). J Soc Cardiovasc Angiogr Interv 2025;4(8):103729
Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases — Hepatology (Biggins SW, Angeli P, Garcia-Tsao G, et al.). Hepatology 2021;74(2):1014-1048
Clinical Pharmacology in Diuretic Use — Clinical Journal of the American Society of Nephrology (Ellison DH). Clin J Am Soc Nephrol 2019;14(8):1248-1257

Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.